newsfilter
← Latest News
GlobeNewswire·

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mes